Merck to disclose some education grants

Share this article:

Merck has announced plans to “enhance transparency” by disclosing certain grants to the public, a company statement said.

The move follows an announcement from Eli Lilly on Sept. 24 that the company will disclose physician payments through an online registry in 2009. 

Although Merck has endorsed congressional legislation (known as the Physician Payments Sunshine Act) which would mandate physician payment disclosure, the company's current plan will only reveal education grants—including accredited CME grants—to “patient organizations, medical professional societies and other organizations…by our Global Human Health division,” according to the statement. Grants will be posted to merck.com beginning in October.

Barring a legislative mandate, however, Merck will begin disclosing physician payments in 2009, and will expand grant disclosures made by two other divisions of the company, according to the statement. Additionally, Merck will continue to disclose results from registered trials of marketed products, regardless of outcome, the statement said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...